



**Dr. Erika Cecchin, PharmD, PhD**

Farmacologia Sperimentale e Clinica  
Centro di Riferimento Oncologico of Aviano - National  
Cancer Institute  
Italy

Erika Cecchin is a researcher of the Clinical and Experimental Pharmacology Unit, of CRO- Aviano where she works on the pharmacogenetic research for the optimization of the chemotherapeutic treatment in cancer. She is author of several full-length publications in international peer reviewed journals and chapters in international books. In 2010 she has been awarded with the “Guido Berlucchi Foundation” prize for young researchers. She is a member of the scientific board of a recently constituted CRO spin-off (PharmaDIAGEN), with the mission to perform pharmacogenetic research and to integrate it in the clinical practice, by the production of commercial pharmacogenetic/ genomic diagnostic kits. Main focus of her researches is the identification of innovative approaches for tailoring anti-cancer treatments based on the genetic characteristics of the patients. The major objective of her studies is to deeply understand the role of genetic markers (polymorphisms) involved in the pharmacokinetics and pharmacodynamics of anti-cancer drugs and to translate such knowledge into the clinical setting, to improve the pharmacological intervention in cancer treatment.

**Selected references:**

1. Cecchin E, Perrone G, Nobili S, Polesel J, De Mattia E, Zanusso C, Petreni P, Lonardi S, Pella N, D'Andrea M, Errante D, Rizzolio F, Mazzei T, Landini I, Mini E, Toffoli G. “MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin” *The Pharmacogenom J*, 15:219-225 2015.
2. De Mattia E, Toffoli G, Polesel J, D'Andrea M, Corona G, Zagonel V, Buonadonna A, Dreussi E, and Cecchin E. “Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment” *Pharmacogenet and Genom* 23(10):549-57 2013.
3. Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, and Innocenti F: „Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer“ *J Clin Oncol* 28:866-71, 2010.
4. Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, and Toffoli G: „Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan“ *J Clin Oncol* 27:2457-65, 2009.
5. Cecchin E, Corona G, Masier S, Biason P, Cattarossi G, Frustaci S, Buonadonna A, Colussi A, and Toffoli G: „Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients“ *Clin Cancer Res* 11:6901-7, 2005.